Combining options in metastatic prostate cancer

Ryan P. Kopp, Tomasz M. Beer

Research output: Contribution to journalComment/debatepeer-review

1 Scopus citations


Intensifying systemic therapy improves outcomes in metastatic prostate cancer. As apalutamide and enzalutamide join abiraterone and docetaxel as treatment options for patients, the choice of therapy for individual patients becomes more complex. We anticipate precision targeted and immune therapies will build on the advances of recently completed large-scale trials.

Original languageEnglish (US)
Pages (from-to)569-570
Number of pages2
JournalNature Reviews Urology
Issue number10
StatePublished - Oct 1 2019

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Combining options in metastatic prostate cancer'. Together they form a unique fingerprint.

Cite this